Publication Discovery of GNE-502 as an Orally Bioavailable and Potent Degrader for Estrogen Receptor Positive Breast Cancer (Bioorganic & Medicinal Chemistry Letters, 2021) Learn More
Publication GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer (ACS Publications, 2021) Learn More
